Abstract OT3-1-11: tnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer

Triple Negative ◽

Randomized Study ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Abstract P5-15-03:nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial

10.1158/1538-7445.sabcs16-p5-15-03 ◽

2017 ◽

Cited By ~ 6

Author(s):

D Yardley ◽

R Coleman ◽

P Conte ◽

J Cortes ◽

A Brufsky ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Randomized Phase 2 ◽

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05070-2 ◽

2018 ◽

Vol 174 (2) ◽

pp. 433-442 ◽

Cited By ~ 17

Author(s):

O. Nanni ◽

◽

D. Amadori ◽

A. De Censi ◽

A. Rocca ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Clinical Trial ◽

Randomized Phase 2 ◽

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Annals of Oncology ◽

10.1093/annonc/mdy201 ◽

2018 ◽

Vol 29 (8) ◽

pp. 1763-1770 ◽

Cited By ~ 30

Author(s):

D.A. Yardley ◽

R. Coleman ◽

P. Conte ◽

J. Cortes ◽

A. Brufsky ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.12.012 ◽

2020 ◽

Vol 20 (3) ◽

pp. 228-237 ◽

Cited By ~ 1

Author(s):

Noha Rashad ◽

Thoraya Abdelhamid ◽

Samia A. Shouman ◽

Hanan Nassar ◽

Mervat A. Omran ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

Abstract OT2-2-01: tnAcity: A phase II/III trial ofnab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)

10.1158/1538-7445.sabcs14-ot2-2-01 ◽

2015 ◽

Author(s):

Denise A Yardley ◽

Robert E Coleman ◽

Pierfranco Conte ◽

Joyce O'Shaughnessy ◽

Javier Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer

Medical Oncology ◽

10.1007/s12032-010-9754-2 ◽

2010 ◽

Vol 28 (S1) ◽

pp. 142-151 ◽

Cited By ~ 3

Author(s):

M. Ghosn ◽

P. Aftimos ◽

F. S. Farhat ◽

J. G. Kattan ◽

C. Hanna ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Randomized Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Weekly Docetaxel ◽

Her 2 ◽

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

European Journal of Cancer ◽

10.1016/j.ejca.2014.10.008 ◽

2014 ◽

Vol 50 (18) ◽

pp. 3077-3088 ◽

Cited By ~ 16

Author(s):

S.W. Lam ◽

S.M. de Groot ◽

A.H. Honkoop ◽

A. Jager ◽

A.J. ten Tije ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Locally Recurrent ◽

Abstract CT212: A phase III randomized study of paclitaxel (T) and trastuzumab (H) versus T, H and lapatinib (L) in first line treatment of HER2+ metastatic breast cancer (MBC)

10.1158/1538-7445.am2020-ct212 ◽

2020 ◽

Author(s):

John Crown ◽

William Jacot ◽

Denis M. Collins ◽

Linda Coate ◽

Anna Saetersdal ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Study ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer

Oncotarget ◽

10.18632/oncotarget.18539 ◽

2017 ◽

Vol 8 (45) ◽

pp. 79527-79536 ◽

Cited By ~ 2

Author(s):

Jian Zhang ◽

Leiping Wang ◽

Zhonghua Wang ◽

Biyun Wang ◽

Jun Cao ◽

...

Keyword(s):

Breast Cancer ◽

Low Dose ◽

Triple Negative ◽

Metastatic Breast ◽

Oral Cyclophosphamide ◽

Line Treatment ◽

First Line ◽

Tnacity: a Phase Ii/Iii Trial of Nab-Paclitaxel (Nab-P) Plus Either Gemcitabine (Gem) or Carboplatin (Carbo) Vs Gem/Carbo As First-Line Treatment for Triple-Negative Metastatic Breast Cancer (Tnmbc)

Annals of Oncology ◽

10.1093/annonc/mdu329.62 ◽

2014 ◽

Vol 25 ◽

pp. iv135

Author(s):

P.F. Conte ◽

D.A. Yardley ◽

A. Brufsky ◽

R.E. Coleman ◽

J. Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽